Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia.
Humans
Uterine Cervical Dysplasia
/ immunology
Female
Uterine Cervical Neoplasms
/ immunology
Loss of Heterozygosity
Histocompatibility Antigens Class I
/ immunology
Papillomavirus Infections
/ immunology
Antigen Presentation
/ immunology
Adult
Alleles
Papillomaviridae
/ immunology
Immunologic Surveillance
Middle Aged
Genotype
HLA class I
cervical cancer
cervical intraepithelial neoplasm
human papillomavirus
loss of heterozygosity
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
28
03
2024
received:
29
01
2024
accepted:
18
04
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
ppublish
Résumé
Loss of heterozygosity (LOH) has been reported to occur in HLA regions in cervical intraepithelial neoplasia (CIN) and cervical cancer. However, the details of how this is related to the progression of CIN have been unclear. In this study, we examined the human papillomavirus (HPV) antigen-presenting capacity of people with CIN and the significance of LOH of HLA class I in the progression of CIN. It was shown that differences in antigen-presenting capacity among each case depended on HLA types, not HPV genotypes. Focusing on the HLA type, there was a positive correlation between antigen-presenting capacity against HPV and the frequency of allelic loss. Furthermore, the lost HLA-B alleles had a higher HPV antigen-presenting capacity than intact alleles. In addition, frequency of LOH of HLA class I was significantly higher in advanced CIN (CIN2-3) than in cervicitis or early-stage CIN (CIN1): around half of CIN2-3 had LOH of any HLA class I. Moreover, the antigen-presenting capacity against E5, which is the HPV proteins that facilitate viral escape from this immune surveillance by suppressing HLA class I expression, had the most significant impact on the LOH in HLA-B. This study suggests that HPV evades immune surveillance mechanisms when host cells lose the capacity for antigen presentation by HLA class I molecules, resulting in long-term infection and progression to advanced lesions.
Substances chimiques
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15509Subventions
Organisme : The Japan Society for the Promotion of Science (JSPS)
ID : 21H02772
Organisme : The Japan Society for the Promotion of Science (JSPS)
ID : 22K09566
Organisme : The Japan Society for the Promotion of Science (JSPS)
ID : 21K15072
Organisme : Japan Agency for Medical Research and Development
ID : JP21cm0106502
Organisme : Japan Agency for Medical Research and Development
ID : JP22ck0106723
Organisme : Japan Agency for Medical Research and Development
ID : JP22ck0106724
Organisme : Japan Agency for Medical Research and Development
ID : JP23ama221528
Organisme : Japan Agency for Medical Research and Development
ID : JP16ck0106178
Organisme : Japan Agency for Medical Research and Development
ID : JP22wm0325014
Organisme : Japan Agency for Medical Research and Development
ID : JP23wm0325057
Organisme : Chiba Prefecture Budget
Organisme : The Seiichi Imai Memorial Foundation
Organisme : Taiju Life Social Welfare Foundation
Organisme : Takeda Science Foundation
Organisme : Princess Takamatsu Cancer Research Fund
Organisme : Uehara Memorial Foundation
Organisme : NOVARTIS Foundation (Japan) for the Promotion of Science
Organisme : Kobayashi Foundation for Cancer Research
Organisme : The Kashiwado Memorial Foundation
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7‐30. doi:10.3322/caac.21332
Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: screening, diagnosis and staging. J BUON. 2016;21(2):320‐325.
Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342‐350. doi:10.1038/nrc798
Ronco G, Giorgi‐Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249‐257. doi:10.1016/S1470‐2045(09)70360‐2
Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880‐890. doi:10.1016/S1470‐2045(11)70188‐7
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890‐907. doi:10.1016/s0140‐6736(07)61416‐0
Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV‐mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208(2):152‐164. doi:10.1002/path.1866
Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):553‐560. doi:10.1158/1055‐9965.EPI‐12‐1406
Chen HC, Schiffman M, Lin CY, et al. Persistence of type‐specific human papillomavirus infection and increased long‐term risk of cervical cancer. J Natl Cancer Inst. 2011;103(18):1387‐1396. doi:10.1093/jnci/djr283
Rodríguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100(7):513‐517. doi:10.1093/jnci/djn044
Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl 1):S16‐S22. doi:10.1016/j.vaccine.2005.09.002
Renoux VM, Bisig B, Langers I, et al. Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol. 2011;41(11):3240‐3252. doi:10.1002/eji.201141693
Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol. 2022;22(2):112‐123. doi:10.1038/s41577‐021‐00558‐3
Hansen TH, Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol. 2009;9(7):503‐513. doi:10.1038/nri2575
Campo MS, Graham SV, Cortese MS, et al. HPV‐16 E5 down‐regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology. 2010;407(1):137‐142. doi:10.1016/j.virol.2010.07.044
Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, Blair GE. High‐risk human papillomavirus E7 expression reduces cell‐surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene. 2008;27(12):1794‐1799. doi:10.1038/sj.onc.1210798
Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1(1):41‐49. doi:10.1038/35095564
Ljunggren HG, Kärre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237‐244. doi:10.1016/0167‐5699(90)90097‐s
Arias‐Pulido H, Joste N, Wheeler CM. Loss of heterozygosity on chromosome 6 in HPV‐16 positive cervical carcinomas carrying the DRB1*1501‐DQB1*0602 haplotype. Genes Chromosomes Cancer. 2004;40(4):277‐284. doi:10.1002/gcc.20048
Chatterjee A, Pulido HA, Koul S, et al. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions. Cancer Res. 2001;61(5):2119‐2123.
Chambuso R, Kaambo E, Denny L, et al. Investigation of cervical tumor biopsies for chromosomal loss of heterozygosity (LOH) and microsatellite instability (MSI) at the HLA II Locus in HIV‐1/HPV co‐infected women. Front Oncol. 2019;9:951. doi:10.3389/fonc.2019.00951
Vermeulen CF, Jordanova ES, Zomerdijk‐Nooijen YA, ter Haar NT, Peters AA, Fleuren GJ. Frequent HLA class I loss is an early event in cervical carcinogenesis. Hum Immunol. 2005;66(11):1167‐1173. doi:10.1016/j.humimm.2005.10.011
Kawazu M, Ueno T, Saeki K, et al. HLA class I analysis provides insight into the genetic and epigenetic background of immune evasion in colorectal cancer with high microsatellite instability. Gastroenterology. 2022;162(3):799‐812. doi:10.1053/j.gastro.2021.10.010
McGranahan N, Rosenthal R, Hiley CT, et al. Allele‐specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259‐1271.e11. doi:10.1016/j.cell.2017.10.001
Azuma Y, Kusumoto‐Matsuo R, Takeuchi F, et al. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol. 2014;44(10):910‐917. doi:10.1093/jjco/hyu112
Estrade C, Menoud PA, Nardelli‐Haefliger D, Sahli R. Validation of a low‐cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol. 2011;49(10):3474‐3481. doi:10.1128/JCM.05039‐11
Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan‐4.1 and NetMHCIIpan‐4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449‐W454. doi:10.1093/nar/gkaa379
Onuki M, Matsumoto K, Satoh T, et al. Human papillomavirus infections among Japanese women: age‐related prevalence and type‐specific risk for cervical cancer. Cancer Sci. 2009;100(7):1312‐1316. doi:10.1111/j.1349‐7006.2009.01161.x
Garland SM, Bhatla N, Ngan HY. Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1414‐1422. doi:10.1158/1055‐9965.EPI‐12‐0164
Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol. 2007;8(10):1041‐1048. doi:10.1038/ni1516
Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV‐associated oropharyngeal cancer. Oral Oncol. 2014;50(5):380‐386. doi:10.1016/j.oraloncology.2013.12.019
Krzowska‐Firych J, Lucas G, Lucas C, Lucas N, Pietrzyk Ł. An overview of human papillomavirus (HPV) as an etiological factor of the anal cancer. J Infect Public Health. 2019;12(1):1‐6. doi:10.1016/j.jiph.2018.06.005
Hosono S, Kawase T, Matsuo K, et al. HLA‐A alleles and the risk of cervical squamous cell carcinoma in Japanese women. J Epidemiol. 2010;20(4):295‐301. doi:10.2188/jea.je20090155
Madeleine MM, Johnson LG, Smith AG, et al. Comprehensive analysis of HLA‐A, HLA‐B, HLA‐C, HLA‐DRB1, and HLA‐DQB1 loci and squamous cell cervical cancer risk. Cancer Res. 2008;68(9):3532‐3539. doi:10.1158/0008‐5472.CAN‐07‐6471
Masuda T, Ito H, Hirata J, et al. Fine mapping of the major histocompatibility complex region and association of the HLA‐B*52:01 allele with cervical cancer in Japanese women. JAMA Netw Open. 2020;3(10):e2023248. doi:10.1001/jamanetworkopen.2020.23248
Leo PJ, Madeleine MM, Wang S, et al. Defining the genetic susceptibility to cervical neoplasia‐a genome‐wide association study. PLoS Genet. 2017;13(8):e1006866. doi:10.1371/journal.pgen.1006866
Chen D, Juko‐Pecirep I, Hammer J, et al. Genome‐wide association study of susceptibility loci for cervical cancer. J Natl Cancer Inst. 2013;105(9):624‐633. doi:10.1093/jnci/djt051
Gokhale P, Mania‐Pramanik J, Sonawani A, et al. Cervical cancer in Indian women reveals contrasting association among common sub‐family of HLA class I alleles. Immunogenetics. 2014;66(12):683‐691. doi:10.1007/s00251‐014‐0805‐2
Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA‐C allotype recognition. J Immunol. 1998;161(2):571‐577.
Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA‐B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995;181(3):1133‐1144. doi:10.1084/jem.181.3.1133
Montesion M, Murugesan K, Jin DX, et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 2021;11(2):282‐292. doi:10.1158/2159‐8290.CD‐20‐0672
Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76‐79. doi:10.1126/science.2157286
Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus‐16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934‐937. doi:10.1126/science.2537532
Bhatt KH, Neller MA, Srihari S, et al. Profiling HPV‐16‐specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. J Exp Med. 2020;217(10):e20200389. doi:10.1084/jem.20200389
Miyauchi S, Kim SS, Jones RN, et al. Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep. 2023;42(5):112508. doi:10.1016/j.celrep.2023.112508
Miyauchi S, Sanders PD, Guram K, et al. HPV16 E5 mediates resistance to PD‐L1 blockade and can be targeted with rimantadine in head and neck cancer. Cancer Res. 2020;80(4):732‐746. doi:10.1158/0008‐5472.CAN‐19‐1771
Hui C, Bai H, Liu J, et al. Accuracy of HPV E6/E7 mRNA examination using in situ hybridization in diagnosing cervical intraepithelial lesions. Diagn Pathol. 2021;16(1):13. doi:10.1186/s13000‐021‐01072‐9